Levothyroxine is used to treat an underactive thyroid (hypothyroidism) by replacing the thyroid hormone that your body isn't making enough of. It helps restore normal metabolism and energy levels.[2] Synthroid is currently approved and in use across 22 indications[4].[1]
Synthroid is one of 352 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
540 competitors in Chronic Kidney Disease
Synthroid
Aranesp
Uloric
Sovaldi
Glucotrol
Vemlidy
Lorelco
Flomax
Miochol
Genotropin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Aug 21, 2000
UNITHROID
NDA NDA021210
May 25, 2001
LEVOXYL
NDA NDA021301
Mar 1, 2002
LEVO-T
NDA NDA021342
May 31, 2002
EUTHYROX
NDA NDA021292
Jul 24, 2002
SYNTHROID
NDA NDA021402
Oct 24, 2002
THYRO-TABS
NDA NDA021116
Jun 6, 2003
LEVOLET
NDA NDA021137
Aug 1, 2007
TIROSINT
NDA NDA021924
Jun 24, 2011
LEVOTHYROXINE SODIUM
NDA NDA202231
Dec 15, 2016
TIROSINT-SOL
NDA NDA206977
Apr 11, 2019
LEVOTHYROXINE SODIUM
NDA NDA210632
Nov 30, 2020
THYQUIDITY
NDA NDA214047
May 17, 2021
LEVOTHYROXINE SODIUM
NDA NDA214253
Apr 29, 2022
ERMEZA
NDA NDA215809
Sources
Details